Asset Details
Do you wish to reserve the book?
Effect and Safety of Finerenone in Patients with IgA Nephropathy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effect and Safety of Finerenone in Patients with IgA Nephropathy
Do you wish to request the book?
Effect and Safety of Finerenone in Patients with IgA Nephropathy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effect and Safety of Finerenone in Patients with IgA Nephropathy
2025
Overview
The study aimed to retrospectively evaluate the efficacy and safety of finerenone in patients diagnosed with IgA nephropathy.
42 IgA nephropathy patients treated with finerenone combined with renin-angiotensin system inhibitor (RASI) and 42 patients who received RASI monotherapy were included in this study. The follow-up duration was 3 months. The efficacy and safety of finerenone were assessed based on key parameters, including urine protein creatinine ratio (UPCR), estimated glomerular filtration rate (eGFR), serum creatinine, serum albumin, hematuria, and serum potassium at 1 and 3 months after treatment initiation.
This study demonstrated that finerenone combined with RASI significantly reduced proteinuria in IgA nephropathy patients. Two-way repeated measures ANOVA revealed a significant time * treatment interaction (
= 0.032), and subsequent one-way repeated measures ANOVA showed a marked decline in log-transformed UPCR over time in the combination group (P < 0.001) but not in the monotherapy group (P = 0.187). Correspondingly, the combination group achieved a 27.29% reduction in UPCR at one month (95% CI: 13.47-39.68%, P = 0.017) and a 34.17% reduction at three months (95% CI: 21.84-52.75%, P < 0.001) compared to baseline, whereas RASI monotherapy failed to show any significant proteinuria-reduction effects. Notably, the antiproteinuric effect was consistent across subgroups. Serum potassium and creatinine levels remained stable, and no adverse events related to hyperkalemia were observed.
The retrospective evaluation suggests that finerenone combined with RASI effectively reduced proteinuria in IgA nephropathy patients, underscoring its potential as a viable treatment option for this patient population.
We currently cannot retrieve any items related to this title. Kindly check back at a later time.